Unicycive Therapeutics earnings release, August 12, 2026
Unicycive
Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
-
Company expects to resubmit New Drug Application (NDA) for oxylanthanum carbonate (OLC) assuming completion of successful inspection of third-party manufacturing vendor
-
FDA has assigned a facility inspection to third-party manufacturing vendor of OLC
-
As of June 30, 2026, unaudited cash, cash equivalents, and marketable securities totaled $61.4 million, with expected runway into 2027
MOUNTAIN
VIEW, Calif., August 12, 2026 --
Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the second quarter ended June 30, 2026, and provided a business update.
“We are focused on securing approval of oxylanthanum carbonate (OLC) and remain confident in the efficacy and safety of OLC and in its potential to improve care for patients with hyperphosphatemia on dialysis,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive.
“The latest update from our third-party manufacturing vendor is that the U.S. Food and Drug Administration (FDA) has assigned a facility inspection. This marks a positive step forward, and our dialogue with the FDA on OLC labeling and packaging has been productive and continuous throughout this process. We are optimistic about a successful inspection of the third-party manufacturing facility, which would enable us to promptly resubmit the NDA. In the meantime, we are well positioned to launch OLC as quickly as possible following potential approval, and we are utilizing this time to continue to expand market awareness in preparation for the commercial success of
OLC.”
Key
Highlights & Upcoming Milestones
Financial
Results for the Quarter Ended June 30, 2026
Research and Development (R&D) expense was $2.8 million for the quarter ended June 30, 2026, compared to $1.8 million for the three months ended June 30, 2025. The increase was primarily driven by a $0.9 million increase in non-cash stock-based compensation, and an increase in consulting and professional fees of $0.1 million.
General and Administrative (G&A) expense was $7.4 million for the quarter ended June 30, 2026, compared to $5.2 million for the three months ended June 30, 2025. The increase was primarily driven by a $1.4 million increase in non-cash stock-based compensation as well as an increase of $0.3 million in other labor costs. There was also an increase of $0.4 million related to commercial launch preparation.
Other income (expense) was $8.4 million for the quarter ended June 30, 2026, compared to $0.5 million income for the three months ended June 30, 2025, attributed primarily to an increase in the fair value of the Company’s warrant liability.
Net loss attributable to common stockholders, basic and diluted, for the quarter ended June 30, 2026, was $(1.7) million, or $(0.06) per share of common stock, compared to $(6.5) million loss, or $(0.52) per share of common stock, for the three months ended June 30, 2025.
The decreased net loss for the quarter ended June 30, 2026, was attributed primarily to a decrease in the fair value of the Company’s warrant liability.
About Unicycive
Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.
Financial statements
Income Statement
Three Months Ended — SOURCE: Unicycive Therapeutics, In
| Three Months Ended – June 30, – 2025 | Three Months Ended – June 30, – 2026 | ||
|---|---|---|---|
| Operating expenses: | Research and development | 1,750 | 2,788 |
| Operating expenses: | General and administrative | 5,213 | 7,352 |
| Operating expenses: | Total operating expenses | 6,963 | 10,140 |
| Operating expenses: | Loss from operations | -6,963 | -10,140 |
| Other income (expenses): | Interest income | 155 | 441 |
| Other income (expenses): | Interest expense | -13 | |
| Other income (expenses): | Change in fair value of warrant liability | 374 | 7,977 |
| Other income (expenses): | Total other income (expenses) | 516 | 8,418 |
| Other income (expenses): | Net loss | -6,447 | -1,722 |
| Other comprehensive loss: | Unrealized loss on marketable securities, net | -29 | |
| Other comprehensive loss: | Net comprehensive loss | -6,447 | -1,751 |
| Other comprehensive loss: | Net loss per share attributable to common stockholders, basic and diluted | -0.52 | -0.06 |
| Other comprehensive loss: | Weighted-average shares outstanding used in computing net loss per share | 12,302,059 | 26,917,266 |
Balance Sheet
As of December 31, 2025 — SOURCE: Unicycive Therapeutics, In
| As of December 31, 2025 | As of June 30, 2026 – (Unaudited) | ||
|---|---|---|---|
| Current assets: | Cash and cash equivalents | 29,198 | 44,185 |
| Current assets: | Prepaid expenses and other current assets | 7,692 | 9,895 |
| Current assets: | Marketable securities | 12,071 | 17,240 |
| Current assets: | Total current assets | 48,961 | 71,320 |
| Current assets: | Right of use asset, net | 108 | 668 |
| Current assets: | Property and equipment, net | 66 | 41 |
| Current assets: | Total assets | 49,135 | 72,029 |
| Current liabilities: | Accounts payable | 383 | 2,234 |
| Current liabilities: | Accrued liabilities | 1,523 | 2,136 |
| Current liabilities: | Warrant liability | 16,915 | 13,718 |
| Current liabilities: | Operating lease liability - current | 117 | 616 |
| Current liabilities: | Total current liabilities | 18,938 | 18,704 |
| Current liabilities: | Operating lease liability – long term | 55 | |
| Current liabilities: | Total liabilities | 18,938 | 18,759 |
| Stockholders’ equity: | Common stock, $0.001 par value per share – 400,000,000 shares authorized at December 31, 2025, and June 30, 2026; 22,114,245 and 27,855,257 shares issued and outstanding at December 31, 2025, and June 30, 2026, respectively | 22 | 28 |
| Stockholders’ equity: | Accumulated other comprehensive loss | -1 | -23 |
| Stockholders’ equity: | Additional paid-in capital | 158,001 | 195,635 |
| Stockholders’ equity: | Accumulated deficit | -127,825 | -142,370 |
| Stockholders’ equity: | Total stockholders’ equity | 30,197 | 53,270 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 49,135 | 72,029 |
Full release
Forward-looking statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.
These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions.
These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; our dependence on third parties for manufacturing; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of our products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled
‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports... (truncated)es and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor
Contacts:
Kevin
Gardner
LifeSci Advisors kgardner@lifesciadvisors.com
Media
Contact:
Unicycive
Therapeutics media@unicycive.com
SOURCE: Unicycive
Therapeutics, In²³⁴